[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE187890T1 - Ligandgerichtete enzyme-prodrug therapie - Google Patents

Ligandgerichtete enzyme-prodrug therapie

Info

Publication number
ATE187890T1
ATE187890T1 AT97901190T AT97901190T ATE187890T1 AT E187890 T1 ATE187890 T1 AT E187890T1 AT 97901190 T AT97901190 T AT 97901190T AT 97901190 T AT97901190 T AT 97901190T AT E187890 T1 ATE187890 T1 AT E187890T1
Authority
AT
Austria
Prior art keywords
prodrug therapy
directed enzyme
enzyme prodrug
ligand directed
ligand
Prior art date
Application number
AT97901190T
Other languages
English (en)
Inventor
Caroline Joy Springer
Richard Marais
Original Assignee
Cancer Res Campaign Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Campaign Tech filed Critical Cancer Res Campaign Tech
Application granted granted Critical
Publication of ATE187890T1 publication Critical patent/ATE187890T1/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Invalid Beds And Related Equipment (AREA)
AT97901190T 1996-01-26 1997-01-24 Ligandgerichtete enzyme-prodrug therapie ATE187890T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9601640.7A GB9601640D0 (en) 1996-01-26 1996-01-26 Ligand directed enzyme prodrug therapy
PCT/GB1997/000221 WO1997026918A2 (en) 1996-01-26 1997-01-24 Ligand directed enzyme prodrug therapy

Publications (1)

Publication Number Publication Date
ATE187890T1 true ATE187890T1 (de) 2000-01-15

Family

ID=10787646

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97901190T ATE187890T1 (de) 1996-01-26 1997-01-24 Ligandgerichtete enzyme-prodrug therapie

Country Status (9)

Country Link
EP (1) EP0876160B1 (de)
JP (1) JP2000504218A (de)
AT (1) ATE187890T1 (de)
AU (1) AU709238B2 (de)
DE (1) DE69700983D1 (de)
GB (1) GB9601640D0 (de)
NZ (1) NZ326436A (de)
WO (1) WO1997026918A2 (de)
ZA (1) ZA97657B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
EP1068338A2 (de) * 1998-03-06 2001-01-17 Oxford Biomedica (UK) Limited Verbesserte 'prodrug'-aktivierung.
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
CA2323071C (en) 1998-03-13 2011-06-21 The Burnham Institute Molecules that home to various selected organs or tissues
US6174687B1 (en) 1999-02-26 2001-01-16 The Burnham Institute Methods of identifying lung homing molecules using membrane dipeptidase
GB9907414D0 (en) 1999-03-31 1999-05-26 Cancer Res Campaign Tech Improvements relating to prodrugs
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
NZ611387A (en) 2002-07-15 2015-05-29 Univ Texas Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
GB0220319D0 (en) 2002-09-02 2002-10-09 Cancer Res Campaign Tech Enzyme activated self-immolative nitrogen mustard drugs
EP2614837A1 (de) 2007-11-09 2013-07-17 Affitech Research AS Anti-VEGF-Antikörperzusammensetzungen und Verfahren
US10947270B2 (en) * 2015-08-27 2021-03-16 National Yang-Ming University Targeted prodrug cytosine deaminase fusion carrier and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308483D0 (en) * 1983-03-28 1983-05-05 Health Lab Service Board Secretion of gene products
WO1992014748A1 (en) * 1991-02-22 1992-09-03 American Cyanamid Company Identification of a novel human receptor tyrosine kinase gene
PT694042E (pt) * 1993-03-25 2005-02-28 Merck & Co Inc Inibidor do factor de crescimento de celulas endoteliais vasculares
AU691820B2 (en) * 1993-07-15 1998-05-28 Cancer Research Campaign Technology Limited Prodrugs of protein tyrosine kinase inhibitors
GB9315494D0 (en) * 1993-07-27 1993-09-08 Springer Caroline Improvements relating to prodrugs
AU702323B2 (en) * 1994-03-15 1999-02-18 Selective Genetics, Inc. Heparin-binding growth factors for gene therapy and anterior eye disorders
WO1996006641A1 (en) * 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
JP2001520503A (ja) * 1994-12-30 2001-10-30 カイロン コーポレイション インビボにおける固形腫瘍の処置のための方法および組成物

Also Published As

Publication number Publication date
JP2000504218A (ja) 2000-04-11
ZA97657B (en) 1997-08-01
WO1997026918A2 (en) 1997-07-31
GB9601640D0 (en) 1996-03-27
WO1997026918A3 (en) 1997-10-23
NZ326436A (en) 1999-03-29
DE69700983D1 (de) 2000-01-27
EP0876160B1 (de) 1999-12-22
AU1453097A (en) 1997-08-20
AU709238B2 (en) 1999-08-26
EP0876160A2 (de) 1998-11-11

Similar Documents

Publication Publication Date Title
ES2143641T3 (es) Expresion en superficie de una enzima en la terapia genica a base de promedicamentos.
AU1916995A (en) 4-amino derivatives of mycophenolic acid with immunosuppressant activity
AU3649397A (en) Precise efficacy assay methods for active agents including chemotherapeutic agents
TNSN97009A1 (fr) 2-oxo- et 2-thio- 1,2- dihydroquinoleinyl-oxazolidinones.
ATE375362T1 (de) Von cyclophilin b abstammende tumorantigen- peptide
AU1917095A (en) 6-substituted mycophenolic and derivatives with immunosuppressive activity
EE200000466A (et) Omeprasooli mikrograanulid, nende valmistamismeetod ja farmatseutilised preparaadid
ATE187890T1 (de) Ligandgerichtete enzyme-prodrug therapie
AU8239298A (en) Nucleotide-comprising composition
MX9805939A (es) Formas solidas de administracion, de liberacion instantanea y procesos para su produccion.
FI963222A0 (fi) 6-substituoitu 4-amino-mykofenolihappo ja sen johdannaiset, joilla on immunosuppressiivista aktiivisuutta
AU1875395A (en) 4-amino derivatives of 5-substituted mycophenolic acid
WO1998024482A3 (de) Verwendung von endothelin-konjugaten in der therapie, neue endothelin-konjugate, diese enthaltende mittel, sowie verfahren zu deren herstellung
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
WO1998050397A3 (de) Chimäre oligonucleotide und ihre verwendung
ZA977895B (en) Transdermal therapeutic system having an active compound combination comprising oestriol.
CA2458872A1 (en) Human ubiquitin-conjugating enzyme
DK1800664T3 (da) Farmaceutiske formuleringer til parenteral indgivelse indeholdende epothilon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties